More focus should be put on determining if pathogens are resistant or resilient to antibiotics, according to a new study. This distinction could allow for improved, personalized treatment and help to preserve current antibiotics.
Take a look behind the scenes of a recent Future Microbiology paper as we ask the authors about the challenges in treating respiratory tract infections and how nanomedicines could help.
Positive results for zoliflodacin, EMA approval for fexinidazole and Merck cuts rotavirus commitment – take a look a the month’s industry headlines.
Researchers from the University of Zurich have discovered that thanatin, a compound produced naturally by the spined soldier bug, could target Gram-negative bacteria by preventing formation of the bacteria’s outer membrane – an unprecedented mechanism.
Take a look at our page for World Antibiotic Awareness Week, including some of our top content from the year, exclusive opinion pieces and a compilation of our #TalkAMR videos!
In line with World Antibiotic Awareness Week we focus on some key statistics and to test the understanding of antibiotic-resistant infections #TalkAMR!
By carefully considering the characteristics of certain old and new antibiotics, it may be possible to overcome many bacterial resistance mechanisms, including when more than one is present.
A Phase II, muti-center, randomized, open-label trial has reported that a novel oral antibiotic, zoliflodacin, is effective in the treatment of uncomplicated urogenital gonorrhea.
A new study from the ECDC has estimated that 33,000 individuals die each year as a consequence of infections with antibiotic-resistant bacteria.
Overcoming intrinsic resistance in Pseudomonas aeruginosa using non-ribosome targeting tobramycin-based adjuvants
In this article, the authors discuss their research using non-ribosome targeting tobramycin-based adjuvants to overcome the intrinsic resistance observed in bacteria, Pseudomonas aeruginosa.